MedTrace Logo

Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma

NCT03526679 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-12-05

Study results available
· View outcomes & findings →

Summary

This study is designed to test the safety and efficacy of the combination of lenvatinib, a drug that can inhibit the growth of supplying vessels around the tumors, and eribulin, a chemotherapy drug that targets the cancer cell during mitosis, in inoperable or metastatic adipocytic sarcoma and leiomyosarcoma.

Conditions

Interventions

DRUG

Eribulin

lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days

DRUG

Lenvatinib

lenvatinib 14mg po daily; eribulin 1.1mg/m2 D1, D8, every 21 days

Sponsors & Collaborators

  • Taipei Veterans General Hospital, Taiwan

    collaborator OTHER_GOV

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Wei-Wu Chen, MD · National Taiwan University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-12
Primary Completion
2021-06-30
Completion
2025-10-30

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03526679 on ClinicalTrials.gov